Tsumura & Co.

4540.T
Drug Manufacturers - Specialty & Generic
2026/01/16 Updated
Market Cap: $2.0B (¥310.7B)
Stock Price: $26.38 (¥4,180)
Exchange Rate: 1 USD = ¥158.48

Stock Price Chart

2026/01/16 Updated
11.51
PER (Price Earnings Ratio)
vs Industry Avg: +2.0
1.06
PBR (Price to Book Ratio)
vs Industry Avg: -0.2
3.64%
Dividend Yield
vs Industry Avg: +0.69%

Price Trend

2026/01/16 Updated
Short-term
5-Day MA
-0.38%
Near-term
25-Day MA
+3.18%
Mid-term
75-Day MA
+9.73%
Long-term
200-Day MA
+12.24%

Price & Trading Details

2026/01/16 Updated

PRICE

Previous Close ¥4,180
Open ¥4,180
High ¥4,192
Low ¥4,131
Close ¥4,180

TRADING

Volume 231,800
Average Volume 380,588
Turnover ¥10億
Min. Purchase ¥418,000

Analyst Recommendations 5 analysts

Updated 2026/01/11
Strong Buy
1
1
Buy
0
Hold
4
4
Sell
0
Strong Sell
0
Target Price (Mean)
¥4,508
None
¥6,140
High
¥4,100
Median
¥3,300
Low
+7% vs Current Price
This information is based on market data from third-party data providers and is for reference only. Investment decisions are your own responsibility.

Shareholder Composition

Updated 2026/01/11
8.4%
Insider Holdings
56.6%
Institutional
35.0%
Public Float
117
Institutional Holders
Insider Holdings 8.4%
Institutional 56.6%
Public Float 35.0%

Major Holders

Updated 2026/01/11
Institution Ownership Shares Change
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
1.27%
972.0K +1.96%
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
0.81%
622.7K +4.20%
Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.
0.64%
489.1K +11.16%
Templeton Global Smaller Companies Fund
0.62%
479.3K 0.00%
Victory Portfolios-Victory Trivalent International Small-Cap Fund
0.57%
435.6K +0.90%
Bridge Builder Trust-Bridge Builder International Equity Fund
0.56%
428.2K +1.88%

Dividend History 3Years Growth

Updated 2026/01/11
-%
Dividend Yield
¥136
Annual Dividend
+15.3%
YoY Growth
31.8%
Payout Ratio
Year Dividend Change
2025 ¥136 +15.3%
2024 ¥118 +76.1%
2023 ¥67 +4.7%
2022 ¥64 0.0%
2021 ¥64 -

Financial Performance

2026/01/11 Updated

Revenue & Profit

Margins

Cash Flow

Financial Health

2022 2023 2024 2025
Income Statement
Revenue ¥129,546M ¥140,043M ¥150,845M ¥181,093M
Gross Profit ¥66,465M ¥68,281M ¥68,816M ¥90,583M
Operating Income ¥22,377M ¥20,916M ¥20,017M ¥40,125M
Pretax Income ¥25,736M ¥23,274M ¥24,066M ¥46,077M
Net Income ¥18,836M ¥16,482M ¥16,707M ¥32,428M
EPS ¥246.21 ¥215.63 ¥219.83 ¥427.15
Operating Margin 17.27% 14.94% 13.27% 22.16%
Balance Sheet
Total Assets ¥350,981M ¥396,813M ¥428,254M ¥464,380M
Total Equity ¥239,769M ¥252,045M ¥270,801M ¥300,528M
Total Liabilities ¥111,212M ¥144,768M ¥157,453M ¥163,852M
Cash ¥67,552M ¥94,752M ¥78,075M ¥73,227M
Interest-bearing Debt ¥49,690M ¥79,690M ¥79,690M ¥70,336M
Equity Ratio 68.31% 63.52% 63.23% 64.72%
D/E Ratio 0.21 0.32 0.29 0.23
Cash Flow
Operating CF ¥21,314M ¥16,452M ¥5,608M ¥33,823M
Investing CF -¥9,111M -¥15,493M -¥19,351M -¥24,974M
Financing CF -¥8,181M ¥24,423M -¥4,417M -¥19,871M
Free CF ¥10,727M ¥1,744M -¥14,449M ¥4,029M
Efficiency
ROE 7.86% 6.54% 6.17% 10.79%
ROA 5.37% 4.15% 3.90% 6.98%

Latest News (5 items)

  • January 16, 2026
    Analyst Rating

    Average Analyst Rating: none

    Average Target Price: ¥4,508
    Rating Score: - (Based on 5 analysts)
    ※1=Strong Buy, 5=Strong Sell

Company Information

English Name Tsumura & Co.
Japanese Name (株)ツムラ
Stock Code 4540.T (JPX)
Sector / Industry Healthcare / Drug Manufacturers - Specialty & Generic
Employees 4,272

About

Tsumura & Co. engages in the production and sale of Kampo extract intermediates and granular Kampo formulations in Japan and internationally. The company offers products for female problems, proneness to fatigue, skin problems, gastrointestinal problems, obesity, constipation and hemorrhoids, as well as body aches, children's sickness, stress, urinary problems, and cold, cough, and nasal and throat inflammation symptoms. It also offers over-the-counter Kampo medicines. The company was founded in 1893 and is headquartered in Tokyo, Japan.

Data provided by Yahoo Finance